Dec 19 2012
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued patent number 8,334,693 (the ‘693 patent), “NMR device for detection of analytes”.
The ‘693 patent covers the T2MR platform, which is used in T2 Bio’s T2Dx device for direct detection of analytes, including T2Candida, the lead product in T2 Bio’s pipeline. T2Candida is a whole blood diagnostic test for the rapid detection of five species of Candida, a fungal pathogen associated with sepsis and the fourth leading hospital-acquired infection in the United States.
“The ‘693 patent, combined with our recently issued patents, underscores T2MR’s unique ability to directly detect immunologic, molecular or hemostasis targets directly from unprocessed samples,” commented John McDonough, President and CEO, T2 Biosystems. “This newly issued patent demonstrates innovations by our team, which is enabling breakthrough diagnostic capabilities for T2Candida and future products for T2 Bio and its partners.”
The claims of the ‘693 patent broadly cover a device for nuclear magnetic resonance (NMR) detection of one or more analytes in a sample with the ability to employ more than one assay workflow for the detection of different analytes, such as nucleic acids, small molecules, proteins and other biologically relevant substances, as well as monitoring these analytes in medical conditions. This patent brings the number of T2 Bio’s U.S. issued patents to six and expands the Company’s IP portfolio related to the Company’s proprietary methods and devices. This patent also covers key aspects of the Company’s NMR-based infectious disease platform including detection of infection, therapeutic management and monitoring of a patient’s response to medical intervention.
Source: http://www.t2biosystems.com/